Study guide
7.2 Compounding Supplies, Containers & Closures
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
7.2 Compounding Supplies, Containers & Closures
Key Takeaways Explain This Topic AI
USP <797> requires supplies that touch the CSP, such as needles, syringes, filters, tubing sets and containers, to be sterile and depyrogenated, and made of materials that do not react with or absorb the ingredients.
Each lot of commercially available sterile, depyrogenated containers and closures needs a certificate of analysis or equivalent documentation. In-house sterilization or depyrogenation must be shown effective (USP <1229>).
Sterilizing filters must be sterile, depyrogenated, 0.22 µm or smaller, and made for pharmaceutical use. A filter labeled 'for laboratory use only' must not be used.
An aqueous multiple-dose CSP must be Category 2 or 3, pass antimicrobial effectiveness testing (USP <51>), and use a container evaluated for closure integrity (USP <1207>).
Container choice affects the BUD (leachables, sorption, freezing, light), and connector design affects safety: ENFit is the enteral standard and NRFit the neuraxial one.
Last updated: September 2026
7.2 Compounding Supplies, Containers & Closures
A CSP is only as good as everything that touches it. Needles, syringes, filters, tubing, bags, vials, stoppers and cassettes can add microbes, endotoxin or particles, and they can react with the drug or absorb it. The BCSCP outline lists compounding supplies (1A3) and containers and closures (1A4) as separate tasks. This section covers both.
USP <797> requirements for supplies (Section 9.2)
Supplies such as beakers, utensils, needles, syringes, filters and tubing sets should be of suitable composition . The surfaces that touch components must not be reactive or sorptive .
Supplies in direct contact with the CSP must be sterile and depyrogenated.
USP's FAQ adds that the chapter does not rule on specific disposable items such as dispensing pins. The facility decides whether a given item is appropriate.
USP <797> requirements for containers and closures
Documentation: Each lot of commercially available sterile, depyrogenated containers and container-closure systems must come with a COA or other documentation showing it meets its sterility and depyrogenation specifications. USP's FAQ accepts supplier labeling that identifies sterile empty bags, with lot traceability.
In-house processing: If the facility sterilizes or depyrogenates its own supplies or containers, it must establish and document that each process works (USP <1229>).
Inspection: Sterile closures are visually reinspected before use for defects that could compromise sterility. Unacceptable lots are rejected, labeled and segregated, and other lots from the same vendor are checked.
How the container shapes the BUD
USP <797> Section 14.2 asks the compounder to consider the materials of composition of the container-closure system and its compatibility with the CSP . That covers leachables, interactions, adsorption and storage conditions.
Container issue Example Consequence
Sorption into plastic Nitroglycerin, amiodarone and tacrolimus in PVC Loss of potency; use polyolefin, glass or non-PVC sets
Leaching of plasticizer DEHP pulled out of PVC by lipids and surfactants (paclitaxel) Patient exposure; use non-PVC containers
Freezing Brittle containers crack when frozen USP requires containers used for frozen CSPs to withstand freezing
Light Photolabile drugs (nitroprusside, dacarbazine) Light-resistant packaging or overwraps
Elastomer interaction Syringe plunger and stopper extractables A stability study must use the same container materials
Headspace and oxygen Oxidation-prone drugs Fill volume, headspace and closure all matter
For Category 3 , the stability study must use a container of the same materials of composition as the one the CSP is actually stored in (see 5.3).
Multiple-dose CSPs
A compounded multiple-dose CSP must be prepared as Category 2 or 3 . If it is aqueous, it must pass antimicrobial effectiveness testing (USP <51>) . Bracketing is allowed across strengths when every other ingredient stays the same. The container must be evaluated for, and meet, container closure integrity (USP <1207>) . Once first entered, it may be used until its BUD or for 28 days, whichever is shorter, provided those limits are supported by the testing. One exception: a nonpreserved aqueous topical or topical ophthalmic multiple-dose CSP needs no USP <51> test if it is Category 2 or 3, for one patient, and labeled to be discarded 24 hours after opening at room temperature or 72 hours refrigerated.
Filters
Filter Specification Use
Sterilizing filter Sterile, depyrogenated, nominal pore 0.22 µm or smaller , made for pharmaceutical use, certified to retain at least 10 7 10^7 1 0 7 Brevundimonas diminuta per cm² Sterilizing filtration; must pass an integrity test after use
"For laboratory use only" filter Not validated for patient use Must not be used to compound CSPs
Prefilter (e.g., 1.2 µm) Larger pore Upstream of the sterilizing filter when the solution carries heavy particulate
Filter needle or straw (commonly 5 µm) Particulate removal Drawing up from glass ampules, one direction only
In-line administration filters 0.2 µm for non-lipid PN and many drugs; 1.2 µm for lipid-containing PN Set by the drug labeling and ASPEN guidance
The designated person must confirm that the chosen sterilizing filter is chemically and physically compatible with the CSP (water-miscible alcohols, for example, can damage some membranes), stable at the pressure and temperature used, and big enough for the volume being filtered.
Syringes, bags, vials and devices
Syringes: Use Luer-lock syringes for transport and caps that keep the tip sterile. Stability data for syringes must match the syringe brand and material when the BUD depends on it.
Bags: Choose PVC, polyolefin or EVA based on drug compatibility. Non-PVC containers are used for drugs that sorb into or leach from PVC.
Glass vials and stoppers: Type I glass. Stopper elastomer (chlorobutyl or bromobutyl) and crimp integrity matter for storage and for coring.
Elastomeric and ambulatory pump reservoirs: BUDs need compatibility and stability data specific to the device.
Connectors that prevent wrong-route errors
Small-bore connectors that are not Luer-compatible make it physically hard to connect a device to the wrong route:
ENFit (ISO 80369-3) for enteral devices, so oral or enteral syringes cannot connect to IV lines.
NRFit (ISO 80369-6) for neuraxial devices (intrathecal and epidural), so IV syringes and lines cannot connect to spinal needles.
For intrathecal and epidural CSPs, NRFit syringes and needles add a physical barrier on top of labeling and independent checks.